Procaps Group SA
NASDAQ:PROC

Watchlist Manager
Procaps Group SA Logo
Procaps Group SA
NASDAQ:PROC
Watchlist
Price: 1.1 USD Market Closed
Market Cap: 124.1m USD

Gross Margin
Procaps Group SA

55.1%
Current
57%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.1%
=
Gross Profit
228m
/
Revenue
414.2m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
LU
Procaps Group SA
NASDAQ:PROC
124.1m USD
55%
US
Eli Lilly and Co
NYSE:LLY
1T USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
68%
CH
Roche Holding AG
SIX:ROG
259.1B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP
82%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
79%
CH
Novartis AG
SIX:NOVN
207.2B CHF
76%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
143.2B USD
75%
No Stocks Found

Procaps Group SA
Glance View

Market Cap
124.1m USD
Industry
Pharmaceuticals

Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

PROC Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.1%
=
Gross Profit
228m
/
Revenue
414.2m
What is the Gross Margin of Procaps Group SA?

Based on Procaps Group SA's most recent financial statements, the company has Gross Margin of 55.1%.

Back to Top